Anti–BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib

The Bruton tyrosine kinase inhibitor (BTKi) ibrutinib has transformed chronic lymphocytic leukemia (CLL) therapy but requires continuous administration. These factors have spurred interest in combination treatments. Unlike with chemotherapy, CD20-directed antibody therapy has not improved the outcom...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: McWilliams, Emily M., Lucas, Christopher R., Chen, Timothy, Harrington, Bonnie K., Wasmuth, Ronni, Campbell, Amanda, Rogers, Kerry A., Cheney, Carolyn M., Mo, Xiaokui, Andritsos, Leslie A., Awan, Farrukh T., Woyach, Jennifer, Carson, William E., Butchar, Jonathan, Tridandapani, Susheela, Hertlein, Erin, Castro, Carlos E., Muthusamy, Natarajan, Byrd, John C.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6373734/
https://ncbi.nlm.nih.gov/pubmed/30737226
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018025684
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados